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There are inadequate data on the outcomes of patients who declined to participate in randomised clinical trials as compared
with those of participants. We retrospectively reviewed the patient characteristics and treatment outcomes of both participants and
non-participants in the two randomised trials for chemotherapy-naive advanced non-small-cell lung cancer. Trial 1 compared four
platinum-based combination regimens. Trial 2 compared two sequences of carboplatin plus paclitaxel and gefitinib therapies.
Nineteen of 119 (16%) and 153 (37%) patients declined to participate in Trials 1 and 2, respectively. Among the background patient
characteristics, the only variable associated with trial participation or declining was the patients’ attending physicians (Po0.001).
Important differences were not observed in the clinical outcomes between participants and non-participants, for whom the response
rates were 30.6 vs 34.2% and the median survival times were 489 vs 461 days, respectively. The hazard ratio for overall survival,
adjusted for other confounding variables, was 0.965 (95% confidence interval: 0.73–1.28). In conclusion, there was no evidence to
suggest any difference in the characteristics and clinical outcomes between participants and non-participants. Trial designs and the
doctor–patient relationship may have an impact on the patient accrual to randomised trials.
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Randomised clinical trials (RCTs) are the definitive method for
comparing the efficacy of treatments and a crucial step in the
development of new cancer treatments. There has always been
a big problem that their low accrual rates limit their progress
(Lara et al, 2001; Corrie et al, 2003; Go et al, 2006).
A number of studies have examined the motivations of patients
for accepting or declining entry to RCTs (Jenkins and Fallowfield,
2000; Madsen et al, 2000, 2002; Ellis et al, 2001; Wright et al, 2004;
Ho et al, 2006; Albrecht et al, 2008). The results of questionnaire
surveys administered to patients regarding clinical trials revealed
that two of the most common reasons for entering the trial were
the hope for personal benefit and the opportunity to contribute to
the research knowledge thereby benefiting others in the future
(Jenkins and Fallowfield, 2000; Madsen et al, 2000, 2002; Ellis et al,
2001; Wright et al, 2004; Albrecht et al, 2008). On the other hand,
the common reasons for declining participation were worries
about the process of randomisation, overestimation of the benefits
of standard therapy and fear of the trial’s experimental nature
(Jenkins and Fallowfield, 2000; Ellis et al, 2001; Ho et al, 2006).
However, inadequate data are available on the actual outcomes
of non-participants compared with those participating in RCTs
(Schmoor et al, 1996; Braunholtz et al, 2001; Burgers et al, 2002;
Peppercorn et al, 2004; West et al, 2005). Although several reports
and their review (Braunholtz et al, 2001) have suggested the
existence of a ‘trial effect’, in which participants enjoy favourable
outcomes, others, especially those which attempted to exclude the
confounding factors, have refuted this finding (Schmoor et al,
1996; Burgers et al, 2002; Peppercorn et al, 2004; West et al, 2005).
On the other hand, if participation in prospective trials is
associated with certain clinical characteristics of the patients,
generalisability of the conclusion from the data to the clinical
practise, even in patients who meet the restrictive eligibility
criteria, should be in question.
The purpose of this study was to analyse the characteristics and
outcomes of the patients who met the eligibility criteria but
declined to participate in RCTs, as compared with those who did
participate, and to search for clues to improve patient accrual to
clinical trials.
MATERIALS AND METHODS
Between October 2000 and October 2005, each of the 272 patients,
who fulfilled the entry criteria of our top priority studies during
the period, was informed of all aspects of RCTs on non-small-cell
lung cancer (NSCLC) and was invited to participate in one of the
two trials to be conducted at the National Cancer Center Hospital,
Tokyo, Japan. We make it a rule for each patient with advanced
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slung cancer to be hospitalised for the first-line chemotherapy. All
patients are then checked for the eligibility criteria of clinical trials
available at the time and recorded in our database, whether or not
they are treated on trials.
Signed informed consent was obtained from the patients for
future statistical analysis of their clinical courses and outcomes,
even when they were treated outside clinical trials.
Trial 1 was conducted to compare the four platinum-based
combination regimens (cisplatin–irinotecan, carboplatin–paclitaxel,
cisplatin–gemcitabine and cisplatin–vinorelbine) in patients with
untreated advanced NSCLC between October 2000 and
June 2002 (Ohe et al, 2007). When patients declined to participate,
cisplatin-based combination regimens, such as cisplatin–irinotecan,
the reference arm of the trial, were recommended. The patients
ultimately selected the treatment following discussions with their
families and the physicians.
Trial 2 was conducted between June 2003 and October 2005 to
compare the following two treatment arms; (A) four courses of
carboplatin and paclitaxel (CP) followed by gefitinib, and (B)
gefitinib until disease progression followed by CP, in patients with
advanced NSCLC (Nokihara et al, 2008). When patients declined to
participate, platinum-based combination regimens, such as CP,
were recommended. The patients ultimately selected the treatment
following discussions with their families and the physicians;
treatment options included gefitinib as first-line chemotherapy,
when the patients and their families wished to start with it.
Patients in each trial had to meet the following criteria: histo-
logically and/or cytologically documented NSCLC; clinical stage IV
or IIIB (including only patients with no indications for curative
radiotherapy); no earlier systematic chemotherapy; at least one
measurable lesion; age 20–74 years old; Eastern Cooperative
Oncology Group Performance Status (PS) of 0 or 1; adequate
haematological, hepatic and renal functions; and partial pressure
of arterial oxygen of 60 torr or more. Each patient was required to
submit a written informed consent before entry.
Four physicians (A, B, C and D) participated in Trial 1 and five
physicians (A, B, C, D and E) in Trial 2. All were male. Physicians
A, B, C and D had 16, 14, 11 and 9 years of experience, respectively,
at the time of activation of Trial 1 (October 2000), and Physician E
had 9 years of experience at the start of Trial 2 (June 2003). One of
the five attending staff physicians and one to two residents or
trainees attended each consultation. Which doctor actually offered
the RCTs depended on each case and was not recorded, but
the attending staff physician finally confirmed the decision by the
patient.
Paper and/or electronic medical records from the initial visit to
our centre to the end of the follow-up were retrospectively
reviewed. Demographic data (age, gender, smoking history),
medical information (tumour histology, clinical stage, perfor-
mance status, therapy characteristics), and clinical outcomes
(response rate, follow-up time, overall survival time, 1- and
2-year survival rates) were abstracted and analysed. The response
was evaluated according to the Response Evaluation Criteria in
Solid Tumours (RECIST) (Therasse et al, 2000) by the attending
physicians. It is our policy to assess clinical responses with
RECIST, even in routine practise. Follow-up time at our institution
was defined as the period from the initiation of the first day of the
initial therapy or decision of no therapy, to the last day at our
institution (including death during follow-up). Survival data of the
patients who left our institution could be collected by enquiry into
official agency for family registry in Japan.
w
2-tests and logistic regression analysis was used to assess asso-
ciations between patient characteristics and the rate of declining to
participate. Overall survival (OS) curves were produced using the
Kaplan–Meier method and compared with the log rank test. All
participants (those who agreed to be enroled into the RCT) and
non-participants (those who declined to participate in the RCT)
were included in the OS analysis. A Cox proportional hazards
model was used to adjust for other potential confounding factors
(age, gender, smoking history, clinical stage and PS) in comparing
the OS of participants and non-participants. P-values o0.05 were
considered statistically significant. The data collected were
analysed using an SPSS II statistical package.
Japanese ethics guidelines for clinical and epidemiological
studies, which took effect in August 2007, do not mandate insti-
tutional review board (IRB) approval for a single-institutional,
retrospective data analysis from the medical charts, when the pre-
designated person of the institution so judges. This study was thus
exempted from ethical review of IRB in due process, on the
judgment of the responsible official, deputy director of National
Cancer Center Hospital.
RESULTS
There were no significant differences in the outcomes between the
arms of each trial. In Trial 1, no statistically significant differences
in the response rate, progression-free survival and OS were
observed between the four regimens. In Trial 2, there were no
statistically significant differences in the median survival time
(MST) (18.8 and 17.2 months) and the survival rate at 1 year
between the two arms. Seventy-five patients declined to participate
in those trials, and 1 of the 197 who initially accepted entry
withdrew consent, refusing to continue the trial immediately after
randomisation.
Table 1 shows the patient characteristics and rate of declining.
100 patients accepted and 19 patients (16%) declined entry to
Trial 1, and 96 patients accepted and 57 patients (37%) declined
entry to clinical Trial 2 (including the one patient already men-
tioned who withdrew consent after randomisation) (Po0.001). No
significant influence on the rate of declining of patient gender, age,
Table 1 Patient characteristics and rate of declining
Clinical trial 1 Clinical trial 2 Total
P NP ROD (%) P NP ROD (%) P NP ROD (%)
No. 100 19 16 96 57 37 196 76 28
Gender
Male 64 12 16 55 34 38 119 46 28
Female 36 7 16 41 23 36 77 30 28
Age
o60 46 9 16 37 29 44 83 38 31
X60 54 10 16 59 28 32 113 38 25
Smoking history
+ 69 9 12 55 33 38 124 43 26
  31 10 24 41 24 37 72 33 31
Clinical stage
III 24 6 20 21 19 48 45 25 36
IV 76 13 15 75 38 34 151 51 25
PS
0 27 4 13 47 19 29 74 23 24
1 73 15 17 49 38 44 122 53 30
Physicians
A 32 5 14 23 25 52 55 30 35
B 2 80 0 2 51 4 5 31 2
C 18 2 10 34 4 11 52 6 10
D 22 12 35 7 18 72 29 30 51
E — — — 79 5 6 79 5 6
Abbreviations: NP¼non-participants, P¼participants; PS¼performance status;
ROD¼rate of declining.
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ssmoking history, tumour histology, clinical stage or PS was
observed (Table 2). There were, however, large differences in the
rates of decline among the attending physicians who informed the
patients about the trials and asked them to participate (Po0.001).
The treatment regimens for those who declined participation in
the clinical trials were as follows. The majority of those who
declined participation in Trial 1 selected one of the four platinum-
based combination regimens presented in the trial: cisplatin–
irinotecan 4, cisplatin–vinorelbine 3, cisplatin–gemcitabine 1,
carboplatin–paclitaxel 4. Three patients in Trial 1 desired to have
no more active treatments and opted for supportive care only,
but later received active treatment at their referred hospitals. The
detail of their therapy is unknown.
The majority of those who declined participation in Trial 2
selected carboplatin-based combination chemotherapy: carbo-
platin–paclitaxel 34 and carboplatin–gemcitabine 11, there by
reflecting the shift to carboplatin for advanced NSCLC in Japan at
the time of Trial 2, on the basis of the reports on the activity of
the carboplatin-based regimens (Kelly et al, 2001; Schiller et al,
2002; Ohe et al, 2007). Twelve patients (21%) selected gefitinib as
first-line chemotherapy.
Survival was analysed for all of the 196 participants and 76
of the non-participants. Post-therapy was analysed for all
of the 196 participants and 73 of the non-participants, who were
treated at our centre. There was one possible treatment-related
death due to perforation of the colon during gefitinib treatment
in Trial 2. No other toxic deaths were observed among either
participants or non-participants. More participants of both
the clinical trials were given four cycles or more of the first-
line chemotherapy, probably reflecting protocol regulations
(Table 3).
Table 4 summarises the treatment after the initial therapy. There
were no significant differences between participants and non-
participants in the number of chemotherapy regimens. Six (8%) of
those who declined participation in the trial later participated in
early-phase clinical trials of experimental therapies.
We have observed no clinically relevant differences in the clinical
outcomes between participants and non-participants (Table 5).
Clinical response to the initial therapy was analysed for all of the 196
participants and 73 of the non-participants, excluding three patients
who were not treated at our institute. The response rate was 30.6% in
participants and 34.2% in non-participants (P¼0.325). The median
follow-up time at our centre was 388 days for participants and 406
days for non-participants, which was not statistically different.
The OS was not different between participants and non-
participants (Table 5 and Figure 1), with a hazard ratio of partici-
pants vs non-participants of 0.998 (95% confidence interval:
0.76–1.32). No significant difference in OS was observed either in
Trial 1 (Figure 2) or in Trial 2 (Figure 3).
Table 2 Prediction of participation or declining to trials
Univariate analysis
a Multivariate analysis
b
Odds ratio (95% CI) P-value Odds ratio (95% CI) P-value
Gender (male vs female) 1.008 (0.586–1.733) 0.977 0.646 (0.300–1.391) 0.264
Age (o60 vs X60) 0.735 (0.432–1.250) 0.254 0.701 (0.376–1.310) 0.266
Smoking history (+ vs  ) 1.394 (0.815–2.386) 0.225 2.538 (1.162–5.541) 0.019
Clinical stage (III vs IV) 0.608 (0.339–1.089) 0.093 0.681 (0.346–1.340) 0.266
PS (0 vs 1) 1.398 (0.792–2.467) 0.247 0.785 (0.396–1.554) 0.487
Physicians (A–E) o0.001 o0.001
Abbreviations: NP¼non-participant; P¼participant; PS¼performance status; ROD¼rate of declining.
aBy Pearson’s w
2-test.
bBy logistic regression analysis.
Table 3 Number of courses of the first-line chemotherapy
Clinical trial 1 Clinical trial 2
Participants Non-participants Participants Non-participants P-value
100 16 96 57
First-line cycles
1 10 (10%) 4 (25%) 6 (12%) 4 (9%) 0.418
a
2 18 (18%) 4 (25%) 8 (16%) 12 (27%)
3 37 (37%) 7 (44%) 5 (10%) 9 (20%)
X4 35 (35%) 1 (6%) 30 (61%) 20 (44%)
Gefitinib median duration (day) 73 99 0.118
b
Range 13–752 34–1065
IQR 29–204 38.5–512
Abbreviation: IQR¼interquartile range.
aBy Pearson’s w
2-test.
bBy log rank test.
Table 4 Treatment after the first-line chemotherapy
Participants Non-participants
196 (%) 73 (%) P-value
a
Chemotherapy regimen
0
b 26 40 0.108
13 8 2 6
22 2 2 5
39 8
445 1
Radiotherapy 49 34 0.031
Pleural or pericardial drainage 10 5 0.227
Operation on metastatic brain
tumors
1 3 0.122
Early-phase trials 13 8 0.300
aBy Pearson’s w
2-test.
bPatients received first-line chemotherapy only.
Participation to randomised trial
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age, smoking history, clinical stage and PS, the hazard ratio of
participants vs non-participants was 0.965 (95% confidence
interval: 0.73–1.28, P¼0.805). Among the patient characteristics,
PS was the only significant factor associated with OS in
multivariate analysis (P¼0.006, by Cox proportional model).
DISCUSSION
It has been argued that trial participants have better outcomes than
those who are not enroled in clinical trials. Several investigations
have reported a favourable overall trend with trial entry
(Braunholtz et al, 2001; Peppercorn et al, 2004; West et al, 2005).
This ‘trial effect’ could derive from several factors, such as protocol
effect (the way treatments are delivered), care effect (extra care
related to data gathering), Hawthorne effect (changes in doctor or
patient behaviour on the basis of the knowledge that they are
under observation) or placebo effect (psychologically mediated
benefits) (Braunholtz et al, 2001; Peppercorn et al, 2004).
In majority of the reports comparing outcomes between
participants and non-participants of clinical trials, however, the
Table 5 Clinical outcomes
Clinical trial 1 Clinical trial 2 Total
Participants Non-participants Participants Non-participants Participants Non-participants P-value
Response rate (%)
a 29 12.5 32.3 40 30.6 34.2 0.569
b
(29/100) (2/16) (31/96) (23/57) (60/196) (25/73)
Median follow-up time (day) 329 339 493 444 388 406 0.846
c
Range 45–2704 1–2176 36–2036 22–1688 36–2704 1–2176
IQR 177–665 59–582 213–861 175–658 197–742 146–604
Median survival time (day) 416 408 573 519 489 461 0.987
c
Range 34–2704 53–2380 40–2036 35–1688 34–2704 35–2380
IQR 264–815 140–698 251–938 276–1012 259–863 229–774
1-year survival (%) 56.0 63.2 65.6 64.9 60.7 64.5 0.567
b
2-year survival (%) 29.4 21.1 38.5 29.8 33.9 27.6 0.379
b
Abbreviation: IQR¼interquartile range.
aExcluding three patients who did not receive active treatment at our center.
bBy Pearson’s w
2-test.
cBy log rank test.
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Figure 1 Overall survival of those who declined to participate in
randomised trials (blue line, n¼76) as compared with the participants (pink
line, n¼196). No significant difference can be observed.
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Figure 2 Overall survival of those who declined to participate in Trial 1
(blue line, n¼19) as compared with the participants (pink line, n¼100).
No significant difference can be observed.
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significant difference can be observed.
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snon-participant ‘controls’ were chosen from differently pooled
database, which could include baseline imbalances between groups
and hindsight bias (Davis et al, 1985; Braunholtz et al, 2001;
Peppercorn et al, 2004). In this study, we compared the
characteristics and outcomes of those who met the eligibility
criteria but declined to participate in randomised trials, and
instead chose to receive standard therapy. We thus aimed at
excluding confounding factors as much as possible.
On the other hand, physician triage is pointed out to be one of
the barriers to cancer clinical trial accrual (Lara et al, 2001; Corrie
et al, 2003; Go et al, 2006; Ho et al, 2006). We excluded the barrier
by making it a rule to offer clinical trials to every patient with
advanced NSCLC who satisfied the eligibility criteria.
The response rate, MST, 1-year and 2-year survival rates were all
similar in both groups. We have to admit that response evaluation
might not be as strict in off-protocol therapy. However, the hazard
ratio for the OS was very close to 1. Although the confidence
interval of 0.73 to 1.28 could not rule out the existence of clinically
important difference in the treatment effect, it could not by any
means be taken as a clinically relevant prognostic factor. We thus
believe this confidence interval of the adjusted hazard ratio, 0.73–
1.28, was narrow enough to justify the conclusion that the clinical
outcomes of trial participants and non-participants were not
different in our study. The differences in the number of cycles of
chemotherapy given to participants and non-participants may
suggest the so-called protocol effect (Braunholtz et al, 2001;
Peppercorn et al, 2004), in which explicit careful description of
treatment regimens could lead to improvement of outcomes. On
the other hand, there clearly existed no ‘care effect’ representing
the differences in incidental aspects of treatment or care between
participants and non-participants, which the protocol may require,
such as extra follow-up or extra nursing care (Braunholtz et al,
2001; Peppercorn et al, 2004). In our cases, the same treatment
teams took charge of and followed both groups of patients in the
same manner, and found no differences in the post-treatment
characteristics or follow-up periods. Thus, our first finding was
that the clinical trials themselves seemed to have no influence on
the outcomes or pattern of care of the patients.
The second finding was that we could not find any demographic
characteristics to influence the patients’ willingness to participate
in clinical trials. Taken together with the first finding, both the
characteristics and outcomes of the non-participants were very
similar to the participants. This would imply that the participants
ably represented the whole patient population of the disease status
who met the eligibility criteria, and that conclusions from the
clinical trials could be generalised.
Our study, however, could only show the similarity in the
prognosis of the participants and non-participants, and, unlike an
earlier report (Link et al, 1986), not that of the treatment effect
itself. This could not be evaluated because there were no significant
differences in the clinical effect between the arms in both Trial 1
and Trial 2. If newer, much more effective experimental treatment
were presented in the trials, the outcome could be better in trial
participants, which was the case in the adjuvant chemotherapy
trial for osteosarcoma (Link et al, 1986). In that report, eligible
patients who declined randomisation, but were given adjuvant
chemotherapy, also had better outcomes. Therefore, a very
effective treatment could lead to a better outcome both on and
off trial. Ideally, strict comparison of the effects of the study
participation itself would require randomised design of the trial
participation (Braunholtz et al, 2001; Peppercorn et al, 2004),
which is almost impossible to conduct.
Thirdly, the declining rate seemed to be influenced by the trial
design. Trial 1 was the comparison of four similar platinum-
doublet regimens. On the other hand, Trial 2 was the comparison
of two arms with sequentially different types of chemotherapy. In
general, people might have the impression that injection therapy
would be more effective, and less convenient, than oral adminis-
tration. It is easy to understand that more patients felt difficulty in
accepting the randomisation of different types of therapy, such as
Trial 2 (Schmoor et al, 1996; Jenkins and Fallowfield, 2000).
The declining rate also seemed to be greatly affected by the
attending physician. The attending physician with longer experience
as a thoracic oncologist tended to have lower rate of declination.
Even though we do not have records on who actually informed the
participants regarding the trial, residents or trainees under Physician
A seemed to have had more chance to lead the consultation, which
might have affected the rate of declination. Trust in the doctor is one
of the most important reasons for agreeing to enter an RCT, whereas
it has also been cited as the main reason for declining to participate
(Jenkins and Fallowfield, 2000; Ellis et al,2 0 0 1 ;S t r y k e ret al, 2006).
Patients prefer the doctor to make the treatment decisions rather
than to be randomised. A recent report emphasises the influence of
physicians’ clinical communication on patients’ decision-making on
participation in clinical trials (Albrecht et al, 2008). Improving
communication and more interventions by clinical research
coordinators and other medical staff members in all eligible patients
may improve the accrual rate (Fallowfield et al, 1998; Wright et al,
2004; Stryker et al, 2006).
Finally, it was interesting to find that 8% of those who declined
the RCTs participated in early-phase trials during follow-up. It is
possible that the lack of effective therapies had changed their
recognition of clinical trials. However, it might support the
psychological states of patients as reported in earlier studies
(Jenkins and Fallowfield, 2000; Ellis et al, 2001; Wright et al, 2004);
patients expect experimental therapies to give them improved
effectiveness but with fear of uncertainty. They are reported to
have negative opinions regarding the principle of randomisation.
Better understanding of the patients’ decision-making process and
the factors influencing their psychological states may lead to
improvement in RCT accrual.
Our study has several limitations. One is that it was conducted at
a single academic institution; the situation might well have been
different in others or when the research was performed on a multi-
institution basis. The second is that we analysed data from only two
trials and could not definitely conclude that a trial design would
affect the patient accrual. Third, we have no data on the reasons for
patient participation. That information would be definitely useful
for analysing factors for consent or declining to participate, and
would help to improve the accrual rate. Further research is required.
In conclusion, there was no evidence of any difference in the
response rates and survival times between participants and non-
participants. The declining rate of clinical trials was influenced by
the referring physicians and trial designs. Further analysis of the
decision-making process of those offered trials is warranted, for it
may improve patient accrual to RCTs.
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